You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

34 Results
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus
Intent: Adjuvant
Funding:
New Drug Funding Program
    Nivolumab - Adjuvant Treatment of Completely Resected Esophageal or Esophagogastric Junction Cancer
Aug 2024
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Adjuvant
Funding:
New Drug Funding Program
    Nivolumab - Adjuvant Treatment of Urothelial Carcinoma
Aug 2024
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Intent: Palliative
Funding:
New Drug Funding Program
    Nivolumab - First-line Treatment of Advanced Gastric, Esophageal, and Esophagogastric Junction Adenocarcinoma
Aug 2024
Regimen
Cancer Type:
Gastrointestinal, 
Hepatobiliary / Liver / Bile Duct
Intent: Palliative
Funding:
New Drug Funding Program
    Durvalumab in combination with Tremelimumab - Previously Untreated Unresectable or Metastatic Hepatocellular Carcinoma (HCC)
New Drug Funding Program
    Durvalumab in combination with Tremelimumab - Previously Untreated Unresectable or Metastatic Hepatocellular Carcinoma (HCC)
Aug 2024
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Neoadjuvant
Aug 2024
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Neoadjuvant
Aug 2024
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Neoadjuvant
Aug 2024
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Neoadjuvant
Aug 2024
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Adjuvant
Aug 2024
Drug
Other Name(s): Yervoy®
Aug 2024

Pages